Developing and advancing dry powder inhalation towards enhanced therapeutics

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 181-194

  Stegemann, S ^a   Kopp, S ^b   Borchard, G ^c   Shah, V P ^d   Senel, S ^e   Dubey, R ^f   Urbanetz, N ^g,h   Cittero, M ⁱ   Schoubben, A ^j   Hippchen, C ^k   Cade, D ^a   Fuglsang, A ⁱ   Morais, J ^l   Borgstrom L ^m   Farshi, F ⁿ   Seyfang, K H ⁱ   Hermann, R ⁱ   Van De Putte, A ^a   Klebovich, I ^o   Hincal, A ^p  

^a CAPSUGEL   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d VPS   (United States)

^e HACETTEPE UNIVERSITY   (Turkey)

^f DR REDDY'S LABORATORIES LTD   (India)

^g GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

^h RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH   (Austria)

ⁱ Plastiape ^*  (Germany)

^j UNIVERSITY OF PERUGIA   (Italy)

^k Geman Federal Institute for Drugs and Medical Devices   (Germany)

^l UNIVERSITY OF LISBON   (Portugal)

^m ASTRAZENECA R AND D   (Sweden)

ⁿ Abdi Ibrahim   (Turkey)

^o SEMMELWEIS UNIVERSITY   (Hungary)

^p IDE   (Turkey)

more..

Author keywords

Affordable medicines; Bioequivalence; Chronic respiratory disease; Dry powder inhalation; Inhalation therapy; Orally inhaled products

Indexed keywords

GENERIC DRUG; LACTOSE; MANNITOL; SALBUTAMOL SULFATE; TERBUTALINE SULFATE;

BIOEQUIVALENCE; BLISTER PACK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COST BENEFIT ANALYSIS; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PACKAGING; DRY POWDER; FORCED EXPIRATORY VOLUME; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; INHALATION DEVICE; LUNG TUBERCULOSIS; METHODOLOGY; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; FEES, PHARMACEUTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY;

EID: 84870289791     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.021     Document Type: Review

References (125)

1. W.P. Adams, S.L. Lee, R. Plourde, R.A. Liionberger, G.M. Bertha, W.H. Doub, J.M. Bovet, and A.J. Hickey Effects of device and formulation on in vitro performance of dry powder inhalers AAPS J. 14 3 2012 400 409
2. W.P. Adams, R.C. Ahrens, M.-L. Chen, D. Christopher, B.A. Chowdhury, D.P. Conner, R. Dalby, K. Fitzgerald, L. Hendeles, A.J. Hickey, G. Hochhaus, L.B. Laube, P. Lucas, S.L. Lee, S. Lyapustina, B. Li, D. O'Connor, N. Parikh, D.A. Parkins, P. Peri, G.R. Pitcairn, M. Riebe, P. Roy, T. Shah, G.J.P. Singh, S. Suarez Sharp, J.D. Suman, M. Weda, J. Woodcock, and L. Yu Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report J Aerosol Med Pulmonary Drug Del 23 1 2010 1 29
3. A.S.M. Afonso, K.M.C. Verhamme, M.C.J.M. Sturkenboom, and G.G.O. Brusselle COPD in the general population: prevalence, incidence and survival Respir. Med. 105 2011 1872 1884
4. P.J. Anderson History of aerosol therapy: liquid nebulization, to MDIs to DPIs Respir. Care 50 9 2005 1139 1150
5. P. Arvidsson, A. Mellen, M. Palmqvist, and J. Lötvall Equivalnet therapeutic ratio of salbutamol given by Turbohaler® and Diskus™ Respir. Med. 94 2000 574 577
6. H. Bagger-Jörgensen, D. Sandell, H. Lundbäck, and M. Sundahl Effect of inherent variability of inhalation products on impactor mass balance limits J. Aerosol. Med. 18 4 2005 367 378
7. P. Begat, D.A.V. Morton, J.N. Staniforth, and R. Price The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics Pharm. Res. 21 10 2004 1826 1833
8. R.S. Benson, and D.J. MacCabe From good manufacturing practice to good manufacturing performance Pharm. Eng. 24 4 2004 26 34
9. C.D. Bresges, and N.A. Urbanetz Determination of the minimum number of spacer particles ensuring non-contact between host particles-a new approach by numerical modelling Powder Technol. 187 2008 260 272
10. P. Blasi, A. Schoubben, S. Giovagnoli, C. Rossi, and M. Ricci Fighting tuberculosis: old drugs, new formulations Exp. Opin. Drug Del. 6 9 2009 977 993
11. K. Blondal, P. Viiklepp, P. Blondal, and A. Altraja Countrywide management of pulmonary tuberculosis reverses increasing incidence Int. J. Tuberc. Lung Dis. 15 7 2011 892 898
12. L. Borgström, E. Derom, E. Stahl, E. Wahlen-Boll, and R. Pauwels The inhalation device influences lung deposition and bronchodilating effect of terbutaline Am. J. Respir. Crit. Care Med. 153 1996 1636 1640
13. L. Borgström, and M. Nilsson A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline Pharm. Res. 7 10 1990 1068 1070
14. A.M. Boshhiha, and N.A. Urbanetz Influence of carrier syrface fines on dry powder inhalation formulations Drug. Dev. Ind. Pharm. 35 8 2009 904 916
15. J. Bousquet, R. Dahl, and N. Khaltaev Global alliance against chronic respiratory diseases Eur. Respir. J. 29 2007 233 239
16. Bousquet, J.; Khaltaev, N.; 2007. Global surveillance, prevention and control of chronic respiratory diseases. World Health Organization. < http://www.who.int/respiratory/publications/global-surveillance/en/index.html >.
17. J.D. Brannan, C. Porsbjerg, and S.D. Anderson Inhaled mannitol as a test for bronchial hyper-resonsiveness Expert. Rev. Respir. Med. 3 5 2009 457 468
18. P.R. Byron, M. Hindle, C.F. Lange, P.W. Longest, D. McRobbie, M.J. Oldham, B. Olsson, C.G. Thiel, H. Wachtel, and W.H. Finlay In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols J. Aerosol. Med. Pulmonary. Drug Del. S2 2010 23 S-59-S-69
19. M. Bur, H. Huwer, L. Muys, and C.M. Lehr Drug transport across pulmonary epithelial cell monomayers: effect of particle size, apical liquid volume, and deposition technique J. Aerosol. Med. Pulmonary Drug Del. 23 3 2010 119 127
20. Center of Disease Control, 2011. Vital signs: asthma prevalence, disease characteristics, and self-management education-United States, 2001-2009. MMWR, vol. 60(17), pp. 547-552.
21. H.-K. Chan What is the role of particle morphology in pharmaceutical powder aerosols? Expert. Opin. Drug Deliv. 5 8 2008 909 914
22. N.Y.K. Chew, B.Y. Shekunov, H.H.Y. Tang, A.H.L. Chow, C. Savage, J. Wu, and H.-K. Chan Effect of amino acids on the dispersion of disodium cromoglycate powders J. Pharm. Sci. 94 10 2005 2289 2300
23. A.H.L. Chow, H.H.Y. Tong, P. Chattopadhyay, and B.Y. Shekunov Particle engineering for pulmonary drug delivery Pharm. Res. 24 3 2007 411 437
24. M.S. Coates, H.-K. Chan, D.F. Fletcher, and J.A. Raper Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size J. Pharm. Sci. 95 6 2006 1382 1392
25. M.S. Coates, H.-K. Chan, D.F. Fletcher, and H. Chiou Influence of mouth piece geometry on the aerosol delivery performance of a dry powder inhaler Pharm. Res. 24 8 2007 1450 1456
26. M.S. Coates, D.F. Fletcher, H.-K. Chan, and J.A. Raper The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses Pharm. Res. 22 6 2005 923 932
27. R.P. Cogdill, T.P. Knight, C.A. Anderson, and J.K. Drennen The financial returns in investments in process analytical technology and lean manufacturing: benchmarks and case study J. Pharm. Innov. 2 2007 38 50
28. N.M. Concessio, M.M. VanOort, M.R. Knowles, and A.J. Hickey Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamics effect Pharm. Res. 16 6 1999 828 834
29. P.T. Daley-Yates The clinical utility of pharmacokinetics in demonstrating bioequivalence of locally acting orally inhaled drugs Respir. Drug Deliv. 1 2010 273 283
30. J.P. De Koning, T.W. van der Mark, P.M.J. Coenegracht, I.F.J. Tromp, and H.W. Frijlink Effect of an external resistance to airflow on the inspiratory flow curve Int. J. Pharm. 234 2002 257 266
31. D.S. Dhanda, and U.B. Kompella Metered dose inhalers (MDIs) and dry powder inhalers (DPIs) for pulmonary drug delivery: CMC issues Clin. Res. Regul. Affairs 22 1 2005 31 55
32. S. Edge, S. Mueller, R. Price, and J. Shur Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products Drug Dev. Ind. Pharm. 34 2008 966 973
33. D. Edwards Applications of capsule dosing techniques for use in dry powder inhalers Ther. Deliv. 1 1 2010 195 201
34. A. Eklund, A. Tronde, I. Johannes-Hellberg, M. Gillen, and L. Borgström Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults Biopharm. Drug Dispos. 29 7 2008 382 395
35. N. El-Gendy, W. Pornputtapitak, and C. Berkland Nanoparticle agglomerates of fluticasone proprionate in combination with albuterol sulfate as dry powder aerosols Eur. J. Pharm. Sci. 44 2011 522 533
36. EMA, 2005. Guidelines on the Pharmaceutical Quality of Inhaled and Nasal Products. EMEA/CHMP/QWP/49313/2005 Corr.
37. EMA, 2009. Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence Between Two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary disease (COPD) in Adults and for use in the Treatment of Asthma in Children and Adolescents. CPMP/EWP/4151/00 Rev. 1.
38. EMEA, 2009. Overview of Comments Received on 'Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence Between two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD)' (CPMP/EWP/4151/00 Rev. 1). EMEA/CHMP/EWP/187653/2009 < http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/09/ WC500096775.pdf >.
39. F. Eskandar, M. Lejeune, and S. Edge Low powder mass filling of dry powder inhalation formulations Drug Dev. Ind. Pharm. 37 1 2011 24 32
40. C. Evans, D. Cipolla, T. Chesworth, E. Agurell, R. Ahrens, D. Conner, S. Dissanayake, M. Dolovich, W. Doub, A. Fuglsang, A.G. Arieta, M. Golden, R. Hermann, G. Hochhaus, S. Holmes, P. Lafferty, S. Lyapustina, P. Nair, D. O'Connor, D. Parkins, I. Peterson, C. Reinser, D. Sandell, G.J.P. Singh, M. Weda, and P. Watson Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop Report J. Aerosol. Med. Pulmonary Drug. Deliv. 25 3 2012 117 139
41. L. Fattorini, E. Iona, M.L. Ricci, O.F. Thoresen, G. Orrù, M.R. Oggioni, E. Tortoli, C. Piersimoni, P. Chiaradonna, M. Tronci, G. Pozzi, and G. Orefici Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis Microb. Drug Resist. 5 1999 260 265
42. FDA, 1998. Guidance to the Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products. Chemistry, Manufacturing and Control Documentation. X: \ CDERGUID \ 2180DFT.WPD.
43. J. Fiegel, L. Garcia-Contrereas, M. Thomas, J. VerBerkmoes, K. Elbert, A.J. Hickey, and D. Edwards Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm. Res. 25 4 2008 805 811
44. T. Freedman Medihaler therapy for bronchial asthma: a new type of aerosol therapy Postgrad. Med. J. 20 1956 667 673
45. Galitsky, C.; Chang, S.-C.; Worrell, E.; Masanet, E.; 2006. Improving Energy Efficiency in Pharmaceutical Manufacturing Operations. Ernest Orlando Lawrence Berkley National Laboratory (LBNL-60288).
46. D. Ganderton General factors influencing drug delivery to the lung Respir. Med. 91 1997 13 16
47. L. Garcia-Contreras, J. Fiegel, M.J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W.A. Germishuizen, P.B. Fourie, A.J. Hickey, and D. Edwards Inhaled lareg porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob. Agents Chemother. 51 8 2007 2830 2836
48. D.E. Geller, J. Weers, and S. Heuerding Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology J. Aerosol. Med. Pulmonary Drug Del. 24 4 2011 175 182
49. A.S. Gershon, J. Guan, C. Wang, and T. To Trends in asthma prevalence and incidence in Ontario, Canada, 1996-2005: a population study Am. J. Epidemiol. 172 6 2010 728 736
50. S. Giovagnoli, P. Blasi, A. Schoubben, C. Rossi, and M. Ricci Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery Int. J. Pharm. 333 2007 103 111
51. D.A. Groneberg, C. Witt, U. Wagner, K.F. Chung, and A. Fischer Fundamentals of pulmonary drug delivery Respir. Med. 97 2003 382 387
52. C. Guo, S.R. Gillespie, J. Kauffman, and W.H. Doub Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen Cascade Impactor and the Next Generation Pharmaceutical Impactor J. Pharm. Sci. 97 8 2008 3321 3334
53. A. Hämmerlein, U. Müller, and M. Schulz Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients J. Eval. Clin. Pract. 17 1 2011 61 70
54. M. Haghi, D. Traini, M. Bebawy, and P.M. Young Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia Mol. Pharm. 9 2012 1717 1726
55. T.W. Harrison, and A.E. Tattersfield Plasma concentrations of fluticonasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects Thorax 58 2003 258 260
56. M.S. Hassan, and R. Lau Effect of particle formulation on dry powder inhalation efficiency Curr. Pharm. Des. 16 2010 2377 2387
57. L. Heifets, J. Simon, and V. Pham Capreomycin is active against non-replicating M. tuberculosis Ann. Clin. Microbiol. Antimicrob. 4 2005 6
58. S. Hein, M. Bur, U.F. Schaefer, and C.-M. Lehr A new pharmaceutical aerosol deposition device on cell cultures (PADDDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations Eur. J. Pharm. Sci. 77 2011 132 138
59. M.P. Holsapple, W.H. Farland, T.D. Landry, N.A. Monteiro-Riviere, J.M. Carter, N.J. Walker, and K.V. Thomas Research strategies for safety evaluation of nanomaterials, Part II: toxicology and safety evaluation of nanomaterials, current challenges and data needs Toxicol. Sci. 88 1 2005 12 17
60. J.C. Hooton, M.D. Jones, H. Harris, J. Shur, and R. Price The influence of crystal habit on the prediction of dry powder inhalation formulation performance using the cohesive-adhesive force balance approach Drug Dev. Ind. Pharm. 34 2008 974 983
61. N. Islam, and E. Gladki Dry powder inhalers (DPI)-a review of device reliability and innovation Int. J. Pharm. 360 2008 1 11
62. W. Janssens, P. VandenBrande, E. Hardeman, E. De Langhe, T. Philips, T. Troosters, and M. Decramer Inspiratory flow rates at different levels of resistance in elderly COPD patients Eur. Respir. J. 31 2008 78 83
63. M.D. Jones, and R. Price The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations Pharm. Res. 23 8 2006 1665 1674
64. M.D. Jones, J.G.F. Santo, B. Yakub, M. Dennison, H. Master, and G. Buckton The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance Int. J. Pharm. 391 2010 137 147
65. Kitamaru, M.; 2012. Glaxo tests cheaper version of Advair for emerging markets. Bloomberg, (9.2.12).
66. N.R. Labiris, and M/B. Dolovich Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications Brit. J. Clin. Pharmacol. 56 2003 600 612
67. B.L. Laube The expanding role of aerosol in systemic drug delivery, gene therapy, and vaccination Respir. Care 50 9 2005 1161 1174
68. V.N.P. Le, T.H. Hoang Thi, E. Robins, and M.P. Flament Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate AAPS PharmSciTech 13 2 2012 477 484
69. C.L. Leach The CFC to HFA transition and its impact on pulmonary drug development Respir. Care 50 9 2005 1201 1208
70. J.B. Lecaillon, G. Kaiser, M. Palmisano, J. Morgan, and G. Della Cioppa Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via aerolizer™ Eur. J. Clin. Pharmacol. 55 1999 131 138
71. S.L. Lee, W.P. Adams, B.V. Vi, D.P. Connor, B.A. Chowdhury, and L.X. Yu In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases AAPS J. 11 3 2009 414 423
72. X. Li, N. Anton, C. Arpagaus, F. Belleteix, and T.F. Vandamme Nanoparticles by spray drying using innovative new technology: the Büchi nano spray dryer B-90 J. Control. Release 147 2 2010 304 310
73. C. LiCalsi, T. Christensen, J.V. Bennett, E. Phillips, and C. Witham Dry powder inhalation as a potential delivery method for vaccines Vaccines 17 1999 1796 1803
74. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
75. S.R. Marek, M.J. Donovan, and H.D.C. Smyth Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy (1): budesonide and lactose Eur. J. Pharm. Biopharm. 78 2011 97 106
76. E.A. Matida, W.H. Finley, M. Breuer, and C.F. Lange Improving prediction of aerosol deposition in an idealized mouth using Large Eddy Simulation J. Aerosol. Med. 19 3 2006 290 300
77. A.S. Melani, D. Zanchetta, N. Barbato, P. Sestini, C. Cinti, P.A. Canessa, S. Aiolfi, and M. Neri Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults Ann. Allergy Asthma Immunol. 93 2004 433 446
78. J. Mitchell, R. Bauer, S. Lyapustina, T. Tougas, and V. Glaab Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs) AAPS PharmSciTech 12 3 2011 965 988
79. J. Mitchell, S. Newman, and H.-K. Chan In vitro and in vivo aspects of cascade impactor test and inhaler performance. A review AAPS PharmSciTech 8 4 2007 E1 E12
80. S. Musafiri, J. van Meerbeeck, L. Musango, G. Brusselle, G. Joos, B. Seminega, and C. Rutayisire Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country Respir. Med. 105 2011 1596 1605
81. Mykhaylova, V.; Dresely, K.; Klar, F.; Urbanetz, N.A.; 2011, Carrier-free formulation of dry powder inhalates-nanoparticle coating of drug microparticles, Pharmind 7, 1324-1331.
82. Newman S.; 2009. Respiratory Drug Delivery. Essential Theory & Practice. RDD online, Richmond, Virginia (USA), pp. 69.
83. S.P. Newman Dry poder inhalers for optimal drug delivery Expert. Opin. Biol. Ther. 4 1 2004 23 33
84. S. Newman, K. Steed, G. Hooper, A. Källen, and L. Borgström Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler Pharm. Res. 12 2 1995 231 236
85. L.M. Niëns, A. Cameron, E. Van de Poel, M. Ewen, W.B.F. Brouwer, and R. Laing Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing World PLoS Med. 7 8 2010 1 8
86. L.M. Nolan, J. Li, L. Tajber, O.I. Corrigan, and A.M. Healy Particle engineering of materials for oral inhalation by dry powder inhalers II-Sodium cromoglicat Int. J. Pharm. 405 2011 36 46
87. D. O'Connor, W.P. Adams, M.-L. Chen, P. Daley-Yates, J. Davis, H. Derendorf, M.P. Ducharme, A. Fuglsang, M. Herrle, G. Hochhaus, S.M. Holmes, S.L. Lee, B.V. Li, S. Lyapustina, S. Newman, M. Oliver, B. Patterson, J. Peart, G. Poochikian, P. Roy, T. Shah, G.J.P. Singh, and S.S. Sharp Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report J. Aerosol. Med. Pulmonary Drug. Deliv. 24 3 2011 119 135
88. M.R. O'Donnell, J. Jarand, M. Loveday, N. Padayatchi, J. Zelnick, L. Werner, K. Naidoo, I. Master, G. Osburn, C. Kvasnovsky, K. Shean, M. Pai, M. Van der Walt, C.R. Horsburgh, and K. Dheda High incidence of hospital admission with multidrug-resistant and extensively drug resistant tuberculosis among South African health care workers Ann. Intern. Med. 153 2010 516 522
89. J. Ooi, D. Traini, S. Hoe, W. Wong, and P.M. Young Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems Int. J. Pharm. 413 2011 1 9
90. U. Petzold, H.-J. Kremer, D.T. Nguyen, U. Munzel, H. Dietrich, and J. Maus Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers J. Aerosol. Med. Pulmonary Drug Deliv. 21 3 2008 309 319
91. A. Qaseem, T.J. Wilt, S.E. Weinberger, N.A. Hanania, G. Criner, T. van der Molen, D.D. Marciniuk, T. Denberg, H. Schuenemann, W. Wedzicha, R. MacDonald, and P. Shekelle Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society Ann. Intern. Med. 155 2011 179 191
92. J. Raula, A. Kuivanen, A. Lähda, and E.I. Kauppinen Gas-phase synthesis of L-leucine-coated micrometer-sized salbutamol sulphate and sodium chmoride particles Powder Technol. 187 2008 289 297
93. J. Raula, F. Thielmann, M. Naderi, V.-P. Lehto, and E.I. Kauppinen Investigations on particle surface characteristics vs. dispersion behavior of L-leucine coated carrier-free inhalable powders Int. J. Pharm. 385 2010 79 85
94. S. Saim, and S.T. Horhota Process for overcoming drug retention in hard gelatin inhalation capsules Drug Dev. Ind. Pharm. 28 6 2002 641 654
95. R.O. Salama, P.M. Young, P. Rogueda, A. Lallement, I. Iliev, and D. Traini Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert Opin. Pharmacother. 12 12 2011 1913 1932
96. B. Schmekel, L. Borgström, and P. Wollmer Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers Thorax 46 1991 225 228
97. A. Schoubben, P. Blasi, S. Giovgnoli, M. Ricci, and C. Rossi Simple and scalable method for peptide inhalable poxder production Eur. J. Pharm. Sci. 39 2010 53 58
98. A. Schoubben, M. Marenzoni, P. Blasi, S. Giovagnoli, M. Coletti, C. Rossi, and M. Ricci Aerodynamic assessment and in vitro evaluation of capreomycin oleate fine powder for tuberculosis therapy AAPS J. 2011 13 S2
99. A. Schoubben, M. Marenzoni, P. Blasi, S. Giovagnoli, M. Ricci, C. Valente, and C. Rossi Production and in vitro evaluation of hydrophocic ion pair fine powders for tuberculosis inhalation therapy AAPS J. 2010 S2
100. Z.T. Selcuk, A.U. Demir, E. Tabakoglu, and T. Caglar Prevalence of asthma and allergic diseases in primary school children in Edirne, Turkey, two surveys 10 years apart Pediatr. Allergy Immunol. 21 2010 e711 e717
101. R. Shrestha, and R. Shakya Comparison of bronchodilator effect of salbutamol delivered via MDI and DPI in COPD patients SAARC J Tuber Lung Dis HIV/AIDS VI 2 2009 22 30
102. I.J. Smith, and M. Parry-Billings The inhaler of the future? A review of dry powder devices on the market today Pulmonary Pharmacol. Ther. 16 2003 79 95
103. Y. Son, M. Horng, M. Copley, and J.T. McConville Optimization of an in vitro dissolution test method for inhalation formulations Dissolution Technol. 17 2 2010 6 13
104. Y. Son, and J.T. McConville Advancements in dry powder delivery to the lung Drug Dev. Ind. Pharm. 34 2008 948 959
105. H. Steckel, and F. Eskandar Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers Eur. J. Pharm. Sci. 19 2003 443 455
106. H. Steckel, P. Markefka, H. teWierik, and R. Kammelar Effect of milling and sieving on functionality of dry powder inhalation products Int. J. Pharm. 309 2006 51 59
107. S. Stegemann, I. Klebovich, I. Antal, H.H. Blume, K. Magyar, G. Németh, T.L. Paál, W. Stumptner, G. Thaler, A. Van de Putte, and V.P. Shah Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products Eur. J. Pharm. Sci. 44 2011 447 454
108. S. Stegemann, J-P. Baeyens, F. Cerreta, E. Chanie, A. Löfgren, M. Maio, G. Schreier, and E. Thesing-Bleck Adherence Measurement Systems and Technology for oral medications in older patient populations Eur Geriatr Med. 3 2012 254 260
109. E. Sternberger-Rützel, W. Runft, M. Beck, E. Weber, M. Kleiner, B. Gimpinger, and I. Müller Quality-by-design: concept for the proof-of-principle testing regarding automated microdosing Pharm. Ind. 74 1 2012 145 154
110. St. Gallen Report, 2006. International benchmarking study: operational Excellence in the Pharmaceutical Industry. University of St. Gallen & APV, 2006.
111. G.V. Taplin, S.H. Cohen, and E.B. Mahoney Prevention of postoperative pulmonary infection JAMA 138 1 1948 4 8
112. K. Thalberg, E. Berg, and M. Fransson Modeling dispersion of dry powders for inhalation. The concept of total fines, cohesive energy and interaction parameters Int. J. Pharm. 427 2012 224 233
113. L. Thorsson, S. Edsbäcker, and T.-B. Conradson Lung deposition of budesonide from Turbohaler is twice that from a pressurized metered-dose inhaler P-MDI Eur. Respir. J. 7 1994 1839 1844
114. A. Tronde, M. Gillen, L. Borgström, J. Lötvall, and J. Ankerst Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD J. Clin. Pharmacol. 48 11 2008 1300 1308
115. United Nations General Assembly resolution 65/1, 2010. < http://www.who.int/nmh/publications/un-resolution65-1/en/ >.
116. W. Van Lerberghe The world health report 2008: primary health care now more than ever World Health Organization ISBN 2008 978 92 4 156373 4
117. J.C. Virchow, C.K. Crompton, R. Dal Negro, S. Pedersen, A. Magnan, J. Seidenberg, and P.J. Barnes Importance of inhaler devices in the management of airways disease Respir. Med. 102 2008 10 19
118. J.G. Weers, J. Bell, H.-K. Chan, D. Cipolla, C. Dunbar, A.J. Hickey, and I.J. Smith Pulmonary formulations: what remains to be done? J. Aerosol. Med. Pulmonary Drug Del. Suppl. 2 2010 23 S5-S23
119. World Health Assembly resolution 52.19. May 24, 1999. WHO's Revised Drug Strategy < http://www.who.int/phi/documents/en/ >.
120. World Health Organization, 2011. Guidelines for the programmatic management of drug-resistant tuberculosis: update 2011. ISBN 978 92 4 150158 3. Geneva, Switzerland. WHO.
121. World Health Organization, 2010. The stop TB strategy. < http://www.who.int/tb/publications/2010/strategy-en.pdf >.
122. B. Wyka, T. Tougas, J. Mitchell, H. Strickland, D. Christopher, and S. Lyapustina Comparison of two approaches for treating cascade impaction mass balance measurements J. Aerosol. Med. 20 3 2007 236 256
123. P.M. Young, S. Edge, D. Traini, M.D. Jones, R. Price, D. El-Sabawi, C. Urry, and C. Smith The influence of dose on the performance of dry powder inhalation systems Int. J. Pharm. 296 2005 26 33
124. P.M. Young, D. Roberts, H. Chiou, W. Rae, H.-K. Chan, and D. Traini Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery J. Aerosol. Sci. 39 2008 82 93
125. X.M. Zeng, G.P. Martin, S.-K. Tee, and C. Marriott The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro Int. J. Pharm. 176 1998 99 110